Summary of minutes of EUCAST Steering Committee Meeting
Stockholm, Sweden, 4-5 July 2016

Attending
Dr Derek F.J. Brown DB Scientific Secretary United Kingdom
Dr Rafael Cantón RC Clinical Data Co-ordinator Spain
Prof Sören Gatermann SG German NAC Germany
Dr Christian Giske CG Chairperson Sweden
Prof Gunnar Kahlmeter GK Technical Data Co-ordinator Sweden
Prof Gerard Lena GL CA-SFM France
Dr P. Christoffer Lindemann CL NWGA Norway
Prof Johan Mouton JM SWAB Netherlands
Prof Alasdair P. MacGowan AM BSAC United Kingdom
Dr Arjana Tambić Andrasevic AT EUCAST General Committee Croatia

Apologies
Dr Deniz Gür DG EUCAST General Committee Turkey

Visiting members
Prof Ron Jones RJ USCAST USA

ECDC representatives (item 17)
Marc Struelens MS ECDC Sweden
Ole Heuer OH ECDC Sweden

1 Chairman’s welcome The new Chairman, CG, welcomed AT as General Committee representative for the next two years, and RJ as visiting GC member from the USA.

2 Minutes of meeting of 12-13 April 2016 With minor corrections the minutes were accepted as a correct record.

3 Matters arising from minutes of 12-13 April 2016 (items not covered by agenda) None.

4 New agents
Ceftazidime-avibactam has been given EU marketing authorisation and EUCAST breakpoints are accepted.

For ceftaroline a dosage and breakpoint variation application has been submitted to EMA and EUCAST will review the impact on breakpoints.

5 EUCAST rationale documents The ceftobiprole rationale document has been released on the website. Telavancin, dalbavancin, oritavancin and tedizolid documents are close to completion. The ceftolozane-tazobactam document is being drafted.

6 Subcommittees
Antifungal susceptibility testing (AFST): It was agreed that totals and percentages could be added to MIC distributions in rationale documents.

Whole genome sequencing (WGS): Comments on the subcommittee report released for wide consultation were reviewed. The subcommittee will be asked to prepare responses to comments and to update the report accordingly.

VetCAST: Possible sources of financial support are being investigated.

MIC distributions and ECOFFs: A discussion document has been drafted.

Antimycobacterial susceptibility testing: The subcommittee has applied to ESCMID for seed funding.

7 Breakpoint issues
A document indicating whether EUCAST breakpoints are available, and if not the reason for the omission, is being prepared. A guidance note on how laboratories should deal with agent-organism combinations without breakpoints is also being prepared.

A guidance note on susceptibility testing of Neisseria gonorrhoeae is to be drafted.
A guidance document on the implications of splitting wild type and resistant populations in breakpoint setting will be released on the EUCAST website.

A guidance document on Legionella pneumophila susceptibility testing will be released on the EUCAST website.

Work on coagulase-negative staphylococci and cefoxitin is in progress.

It was agreed to reduce colistin breakpoints for Pseudomonas spp. to S ≤2, R > 2 mg/L.

A document with modified carbapenem breakpoint proposals is being prepared.

Responses to comments on the consultation document on changes to the intermediate category definition are being prepared.

Intrinsic resistance and unusual resistance tables will be released on the EUCAST website. The expert rule tables are being updated.

Macrolide breakpoints for H. influenzae are currently being reviewed.

Responses to comments on proposed changes to fluoroquinolone breakpoints released for wide consultation were discussed.

Tigecycline breakpoints for Enterobacteriaceae are currently being reviewed.

Data relevant to the setting of temocillin breakpoints are being reviewed.

A presentation and report from USCAST were discussed to initiate a breakpoint review process for aminoglycosides.

Nitrooxoline breakpoints and the rationale document are to be released. A disk diffusion test is being developed.

Azithromycin breakpoints for Neisseria gonorrhoeae will be reviewed.

H. influenzae ampicillin/amoxicillin breakpoints with i.v. and oral dosing are being reviewed.

Organisms without EUCAST breakpoints

Proposals on breakpoints for Aerococcus spp and Kingella kingae are being prepared.

EUCAST methods

Fosfomycin susceptibility testing has been investigated in a collaborative study. Further studies are planned.

It was noted that gradient tests underestimate colistin MICs for Enterobacteriaceae. A warning will be released.

Screening test flow charts for oxacillin with S. pneumoniae and penicillin with H. influenzae will be added under the respective breakpoint tables.

Proposed uniform codes for antimicrobial agents are being discussed.

Implementation of EUCAST breakpoints

No new information.

EUCAST websites

A separate section with all open consultations and responses is being prepared.

Publications and presentations

No new information.

NACs

No new information.

EUCAST documents

A revised version of the EUCAST statutes has been posted on the website.
<table>
<thead>
<tr>
<th></th>
<th>ESCMID</th>
</tr>
</thead>
<tbody>
<tr>
<td>15</td>
<td>The Postgraduate Educational Course 2016 on Antimicrobial susceptibility testing with EUCAST breakpoints and methods has been advertised and course arrangements are in progress. Proposals for ECCMID 2017 have been submitted.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>EMA</th>
</tr>
</thead>
<tbody>
<tr>
<td>16</td>
<td>No new information.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>ECDC</th>
</tr>
</thead>
<tbody>
<tr>
<td>17</td>
<td>Representatives from ECDC attended the Steering Committee meeting for the annual technical liaison and coordination meeting.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>CLSI</th>
</tr>
</thead>
<tbody>
<tr>
<td>18</td>
<td>No new information.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>Any other business</th>
</tr>
</thead>
<tbody>
<tr>
<td>19</td>
<td>None.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>Next meetings</th>
</tr>
</thead>
<tbody>
<tr>
<td>20</td>
<td>19-20 September 2016, Bochum, Germany (before PGEC)</td>
</tr>
<tr>
<td></td>
<td>21-22 November 2016, Windsor, London</td>
</tr>
<tr>
<td></td>
<td>6-7 February 2017, Rotterdam</td>
</tr>
<tr>
<td></td>
<td>25-26 April 2017, Vienna (immediately following ECCMID)</td>
</tr>
<tr>
<td></td>
<td>10-11 July 2017, Stockholm</td>
</tr>
</tbody>
</table>

Ratified summary of minutes of meeting 4-5 July 2016. Prepared by DB, CG, GK and RC